reports
- Roy Külter
- Steven Boumans
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
- Christophe Chaput
Trigano : 2025 set to be a year of strong FCF generation, encouraging ...
Following the first autumn trade shows, Trigano's order book for 2026 looks promising, with double-digit growth. This would suggest 16% growth in the underlying operating profit in 2026 after a return to normalised dealer inventories in 2025, with revenue (published on 24/09/2025) down 6.8% and the operating margin (to be published on 26/11/2025) set to be down 330bp. 2025 is nonetheless set to benefit from excellent FCF generation (>€ 450m), which should beef up an already enviable balance shee...
- Roy Külter
- Steven Boumans
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Christophe Chaput
Trigano : 2025 sera une année de forte génération de FCF. Les premiers...
A l’issue des premiers salons professionnels d’automne, la croissance du carnet de commandes de Trigano pour 2026 s’annonce sous de bons auspices avec une croissance à 2 chiffres. Elle permettrait d’envisager une hausse du ROC 2026e de +16%, après une année 2025 marquée par la normalisation des stocks distributeurs (CA -6.8% déjà publié le 24/09/2025 ; MOP estimée -330 pb publication le 26/11/2025). Néanmoins, l’excellente génération de FCF (> 450 M€) en 2025 devrait renforcer une situation bila...
With the gain of Brazilian contracts, Voltalia has surpassed 8 gigawat...
With the gain of Brazilian contracts, Voltalia has surpassed 8 gigawatts of capacity under management for third parties, reaching its 2027 target two years ahead of schedule With the gain of Brazilian contracts, Voltalia has surpassed 8 gigawatts of capacity under management for third parties, reaching its 2027 target two years ahead of schedule Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the signing of 937 megawatts of new maintenance contracts in Brazil. With these agreements, the capacity operated on be...
Avec le gain de contrats brésiliens, Voltalia franchit le cap des 8 gi...
Avec le gain de contrats brésiliens, Voltalia franchit le cap des 8 gigawatts de capacité en exploitation pour compte de tiers, avec deux ans d’avance sur son objectif 2027 Avec le gain de contrats brésiliens, Voltalia franchit le cap des 8 gigawatts de capacité en exploitation pour compte de tiers, avec deux ans d’avance sur son objectif 2027 Voltalia (Euronext Paris, ISIN code : FR0011995588), acteur international des énergies renouvelables, annonce la signature de 937 mégawatts de nouveaux contrats de maintenance au Brésil. Grâce à ces accords, la capacité opérée pour compte de tiers ...
Transgene Provides Business and Financial Update for Q3 2025
Transgene Provides Business and Financial Update for Q3 2025 Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC) patients, to be presented at SITC 2025 New TG4050 data further validate its mechanism of action and potential to reduce risk of relapse presented at ASCO 2025 First immunogenicity data in the ongoing Phase II trial in operable HNSCC expected in H2 2026 Strasbourg, France, November 4, 2025, 5:50 p.m. CET – Transgene (Euronext Paris: TNG...
Transgene fait le point sur ses activités et sa situation financière a...
Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2025 Présentation au SITC 2025 du profil des réponses immunitaires induites par TG4050, un vaccin thérapeutique individualisé reposant sur des néoantigènes (VTIN) dans l’étude randomisée de Phase I (cancer de la tête et du cou opérable) Les nouvelles données de TG4050 confirment le mécanisme d’action et le potentiel de réduction du risque de rechute, présentées à l’ASCO 2025 Premières données d’immunogénicité de l’étude de Phase II (cancer de la tête et du cou opérable) attendues au deuxième se...
New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s...
New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s ability to induce neoantigen-specific cytotoxic CD8+ T cell responses capable of targeting and eliminating tumor cells, supporting its potential to reduce risk of relapse Conference call scheduled on November 14 at 4 p.m. CET (in English). See details below. Strasbourg, France & Tok...
Les nouvelles données d’immunologie de la Phase I de TG4050 présentées...
Les nouvelles données d’immunologie de la Phase I de TG4050 présentées au SITC 2025 démontrent son potentiel prometteur à réduire le risque de récidive Les nouvelles données mettent en évidence les éléments clés du mécanisme d’action de TG4050, qui induit des réponses immunitaires durables (lymphocytes T CD8+) chez des patients atteints d’un cancer opérable de la tête et du cou Le profil détaillé des réponses immunitaires confirme la capacité de TG4050 à induire des réponses T CD8+ cytotoxiques et spécifiques des néoantigènes contenus dans le vaccin thérapeutiqueCes réponses sont capables...
Corbion reports the progress of its share buyback program 27 October –...
Corbion reports the progress of its share buyback program 27 October – 31 October 2025 Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 27 October up to and including 31 October 2025 a total of 102.003 shares were repurchased at an average price of €17.6450 for a total amount of €1,799,838.05 To date, the total consideration for shares repurchased amounts to 420,203 shares representing 72.40% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progre...
Weekly share repurchase program transaction details
Weekly share repurchase program transaction details Amsterdam, October 29, 2025 SBM Offshore reports the transaction details related to its EUR141 million (c. US$150 million1) share repurchase program for the period October 23, 2025 through October 29, 2025. The repurchases were made under the EUR141 million share repurchase program announced on February 20, 2025 and effective from April 24, 2025. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share re...
- Wim Hoste
Corbion Feedback 3Q results conference call
Below are the key highlights from the 3Q results conference call. 3Q top line was a bit weaker than expected whilst 3Q adjusted EBITDA increased by 11% organically and was in line with our and consensus expectations. Corbion still expects organic EBITDA growth of over 25% which translates into c. € 207m when taking into account the expected negative $ effect (KBCS & CSS € 206m). We continue to appreciate Corbion for its market leadership in lactic acid and growth opportunities within the existin...
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- Luis de Toledo Heras
TEMN TEMENOS AG
SOP SOPRA STERIA GROUP SA
OUT1V OUTOKUMPU OYJ
SBMO SBM OFFSHORE NV
KORI KORIAN SA
TYRES NOKIAN RENKAAT OYJ
ASY ASSYSTEM SA
VETO VETOQUINOL SA
PIG HAULOTTE GROUP SA
CDA COMPAGNIE DES ALPES SA
NOEJ NORMA GROUP SE
BB SOCIETE BIC SA
BAMNB KONINKLIJKE BAM GROEP NV
VID VIDRALA SA
MMT METROPOLE TELEVISION SA
AED AEDIFICA SA
SHOT SCANDIC HOTELS GROUP
WAF SILTRONIC AG
MELE MELEXIS NV
ENC ENCE ENERGIA Y CELULOSA SA
SMHN SUESS MICROTEC AG
ALR ALIOR BANK SA
CSM CORBION NV
SAE SHOP APOTHEKE EUROPE NV
ALD ALD SA
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ALLFG ALLFUNDS (UK) LTD
ORP ORPEA
SHA SCHAEFFLER AG
- ING Helpdesk
Benelux Morning Notes
Adyen: 3Q25 results – solid net revenue, FY25 guidance reiterated. Aedifica: Guidance raised, positive tenant trends and good portfolio valuation. Ageas: China Taiping Life 3Q25 Solvency much lower, remains solid. Allfunds Group PLC: Strong flows. ASM International: 3Q25 results - disappointing orders, much better margins. Corbion: Iron wills and nerves of steel. Lotus Bakeries: peer Mondelez 3Q25 results. Melexis: 3Q25 results, ongoing gross margin pressure. Staffing: Dutch figs...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.